WallStreetZenWallStreetZen

NASDAQ: ARTV
Artiva Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ARTV

Based on 5 analysts offering 12 month price targets for Artiva Biotherapeutics Inc

Min Forecast
$12.00+506.06%
Avg Forecast
$17.60+788.89%
Max Forecast
$20.00+910.1%

Should I buy or sell ARTV stock?

Based on 5 analysts offering ratings for Artiva Biotherapeutics Inc.

Buy
Strong Buy
1 analysts 20%
Buy
4 analysts 80%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ARTV's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ARTV as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ARTV stock forecasts and price targets.

ARTV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-11
lockedlocked$00.00+00.00%2025-05-15
lockedlocked$00.00+00.00%2025-03-26
lockedlocked$00.00+00.00%2025-03-25
lockedlocked$00.00+00.00%2025-03-25

1 of 1

Forecast return on equity

Is ARTV forecast to generate an efficient return?

Company
-30.94%
Industry
140.91%
Market
90.47%
ARTV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ARTV forecast to generate an efficient return on assets?

Company
-27.3%
Industry
32.45%
ARTV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ARTV earnings per share forecast

What is ARTV's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$3.32
Avg 2 year Forecast
-$3.17
Avg 3 year Forecast
-$2.40

ARTV revenue forecast

What is ARTV's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$28.0M
Avg 2 year Forecast
$64.7M
Avg 3 year Forecast
$135.9M

ARTV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARTV$1.98$17.60+788.89%Buy
STTK$1.01$4.00+296.04%Buy
RNXT$1.30$7.25+457.69%Buy
VTVT$15.35$36.00+134.53%Buy
ALGS$7.71$70.00+807.91%Buy
View Top Biotech Stocks

Artiva Biotherapeutics Stock Forecast FAQ

Is Artiva Biotherapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ARTV) stock is to Buy ARTV stock.

Out of 5 analysts, 1 (20%) are recommending ARTV as a Strong Buy, 4 (80%) are recommending ARTV as a Buy, 0 (0%) are recommending ARTV as a Hold, 0 (0%) are recommending ARTV as a Sell, and 0 (0%) are recommending ARTV as a Strong Sell.

If you're new to stock investing, here's how to buy Artiva Biotherapeutics stock.

What is ARTV's earnings growth forecast for 2025-2027?

(NASDAQ: ARTV) Artiva Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Artiva Biotherapeutics's earnings in 2025 is -$71,721,000.On average, 5 Wall Street analysts forecast ARTV's earnings for 2025 to be -$80,788,103, with the lowest ARTV earnings forecast at -$97,452,476, and the highest ARTV earnings forecast at -$74,063,882. On average, 5 Wall Street analysts forecast ARTV's earnings for 2026 to be -$77,328,540, with the lowest ARTV earnings forecast at -$103,543,256, and the highest ARTV earnings forecast at -$52,137,075.

In 2027, ARTV is forecast to generate -$58,391,087 in earnings, with the lowest earnings forecast at -$78,692,874 and the highest earnings forecast at -$39,955,515.

What is ARTV's revenue growth forecast for 2028-2030?

(NASDAQ: ARTV) Artiva Biotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Artiva Biotherapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ARTV's revenue for 2028 to be $683,141,857, with the lowest ARTV revenue forecast at $338,160,092, and the highest ARTV revenue forecast at $1,028,147,985. On average, 3 Wall Street analysts forecast ARTV's revenue for 2029 to be $1,577,438,866, with the lowest ARTV revenue forecast at $7,065,305, and the highest ARTV revenue forecast at $2,869,999,781.

In 2030, ARTV is forecast to generate $3,311,849,308 in revenue, with the lowest revenue forecast at $1,185,996,633 and the highest revenue forecast at $4,814,176,678.

What is ARTV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ARTV) forecast ROA is -27.3%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is ARTV's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ARTV price target, the average ARTV price target is $17.60, with the highest ARTV stock price forecast at $20.00 and the lowest ARTV stock price forecast at $12.00.

On average, Wall Street analysts predict that Artiva Biotherapeutics's share price could reach $17.60 by Jun 11, 2026. The average Artiva Biotherapeutics stock price prediction forecasts a potential upside of 788.89% from the current ARTV share price of $1.98.

What is ARTV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ARTV) Artiva Biotherapeutics's current Earnings Per Share (EPS) is -$22.40. On average, analysts forecast that ARTV's EPS will be -$3.32 for 2025, with the lowest EPS forecast at -$4.00, and the highest EPS forecast at -$3.04. On average, analysts forecast that ARTV's EPS will be -$3.17 for 2026, with the lowest EPS forecast at -$4.25, and the highest EPS forecast at -$2.14. In 2027, ARTV's EPS is forecast to hit -$2.40 (min: -$3.23, max: -$1.64).

What is ARTV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ARTV) forecast ROE is -30.94%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.